MENLO PARK, Calif., Sept. 9, 2020 — GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission (SEC) for a proposed initial public offering of its common stock in the United States. The number of shares to be offered and the price range for the proposed offering have not yet been determined. GRAIL has applied to list its common stock on the Nasdaq Global Select Market under the symbol “GRAL.”
Morgan Stanley, Goldman Sachs & Co. LLC, and BofA Securities will act as lead bookrunners for the proposed offering. Cowen and Evercore ISI will act as additional bookrunners.
The proposed offering will be made only by means of a prospectus. Copies of the preliminary prospectus, when available, may be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, via telephone: 866-471-2526, or via email: prospectus-ny@ny.email.gs.com; BofA Securities, Inc., Attention: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, or by email at dg.prospectus_requests@bofa.com; Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 833-297-2926, or by email at PostSaleManualRequests@broadridge.com; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, New York 10055, by telephone at 888-474-0200, or by email at ecm.prospectus@evercore.com.
A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Investor Contact:
John Craighead
ir@grailbio.com
Media Contact:
Matt Burns
pr@grailbio.com
